Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Mercury Systems (NASDAQ: MRCY ) stock is falling on Tuesday after getting hit with a short report from Glasshouse . That coverage from Glasshouse has it kicking off MRCY stock with a ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology firm Ayala Pharmaceuticals (NASDAQ: AYLA ) is suddenly the center of attention among small-cap traders today. There’s really no significant news concerning the company itself. However, Ayala poste...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off Tuesday with an overview of the biggest pre-market stock movers traders will want to know about! We’ve got reverse stock splits, a hostile takeov...
Gainers: Inotiv ( NOTV ) +18% . IO Biotech ( IOBT ) +16% . SOPHiA GENETICS ( SOPH ) +10% . Apyx Medical ( APYX ) +9% . Rhythm Pharmaceuticals ( RYTM ) +9% . Losers: Regulus Therapeutics ( RGLS ) -14% . Aerovate...
Ayala Pharmaceuticals ( NASDAQ: AYLA ) on Tuesday announced what it deemed to be positive interim results from part A of its ongoing phase 2/3 trial evaluating its inhibitor AL102 in desmoid tumors, which are a type of noncancerous growth that can cause chronic pain. AYLA ...
- Tumor shrink ing observed in substantially all patients who were evaluable at 16 weeks - - Favorable safety results observed : AL102 was well tolerated - - Additional data to be submitted for presen t ...
AL101 Responders Had Significantly Improved Survival. Ayala Pharmaceuticals presented data from the Phase 2 ACCURACY trial testing AL101 in recurrent or metastatic adenoid cystic carcinoma (ACC), a rare tumor of the secretory glands. AL101 is an inhibitor of gamma secretase, an enzyme that act...
-- Presentation at ASCO features updated results from Phase 2 ACCURACY study -- -- AL101 demonstrated anti-tumor activity by achieving an overall disease control rate of 69% -- -- Patients achieving partial responses had higher progression-free survival -- REHOVOT,...
REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in g...
REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in gene...
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...